Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response.
Co-administration of intranasal PT-141 and sildenafil may enhance erectile response in men who do not adequately respond to sildenafil alone.
Where it sits
this study against the rest of the pt-141 (bremelanotide) corpusSummary and findings
This study evaluated the safety and pharmacodynamic effect of co-administering 7.5 mg intranasal PT-141 and 25 mg sildenafil in 19 men with erectile dysfunction. The results indicated that the combination led to a greater erectile response compared to sildenafil alone. No new adverse events were reported.
Abstract
<h4>Objectives</h4>To evaluate the safety and pharmacodynamic effect of co-administration of subtherapeutic doses of PT-141, a cyclic heptapeptide melanocortin analogue, and sildenafil to patients with erectile dysfunction.<h4>Methods</h4>Nineteen patients with erectile dysfunction who were responders to either Viagra or Levitra by self-report were given 25 mg sildenafil and 7.5 mg intranasal PT-141, 25 mg sildenafil and an intranasal placebo spray, and a placebo tablet and an intranasal placebo spray in a randomized cross-over design. Erectile activity in response to two 30-minute episodes of visual sexual stimulation was assessed by RigiScan during a 6-hour postdose period.<h4>Results</h4>The erectile response induced by co-administration of PT-141 and sildenafil was significantly greater than the response elicited by administration of sildenafil alone. Co-administration of PT-141 and sildenafil was safe and well-tolerated and did not result in new adverse events or adverse events that were increased in frequency or severity compared with monotherapy.<h4>Conclusions</h4>Co-administration of intranasal PT-141 and a phosphodiesterase type 5 inhibitor may constitute a treatment alternative for patients in whom higher doses of a single therapy are not effective or well tolerated.
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.